Abcam, ab216311, AZD4547, FGFR inhibitor

Size: 5mg / 25mg
MW 463.6 Da, Purity >98%. Novel, selective inhibitor of the FGFR1, 2, and 3 tyrosine kinases. Binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, thus resulting in the inhibition of tumor cell proliferation and tumor cell death.
Key facts
CAS number:1035270-39-3,
Purity:>98%,
Form:SolidSee storage information,
Molecular weight:463.6 Da,
Molecular formula:C26H33N5O3,
PubChem:51039095,
Nature:Synthetic,
Solubility:DMSO (>80 mg/ml),
Biochemical name:Azd-4547,
Biological description:Novel, selective inhibitor of the FGFR1, 2, and 3 tyrosine kinases. Binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, thus resulting in the inhibition of tumor cell proliferation and tumor cell death.,
Canonical smiles:CC1CN(CC(N1)C)C2=CC=C(C=C2)C(=O)NC3=NNC(=C3)CCC4=CC(=CC(=C4)OC)OC,
Isomeric smiles:C[C@@H]1CN(C[C@@H](N1)C)C2=CC=C(C=C2)C(=O)NC3=NNC(=C3)CCC4=CC(=CC(=C4)OC)OC,
InChi:InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+,
InChiKey:VRQMAABPASPXMW-HDICACEKSA-N,
IUPAC Name:N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3S,5R)-3,5-dimethylpiperazin-1-yl]benzamide

Product details:
This product is manufactured by BioVision, an Abcam company and was previously called 9403 AZD-4547. 9403-25 is the same size as the 25 mg size of ab216311.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information-Store in the dark, Store under desiccating conditions

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
VEGF Receptor 2 also known as KDR or Flk-1 along with FGFR1 FGFR2 FGFR3 and FGFR4 are important targets in cellular signaling pathways. VEGFR2 with a molecular weight of approximately 150 kDa is a tyrosine kinase receptor prominently expressed in vascular endothelial cells. FGFRs share similar functional motifs and are expressed widely with variations in expression in tissue types like mesenchyme and oligodendrocytes. AZD-4547 is known as an FGFR inhibitor specifically targeting these receptors.
Biological function summary
VEGFR2 and FGFRs play roles in angiogenesis and tissue development. VEGFR2 mediates endothelial cell proliferation migration and new blood vessel formation. FGFRs form a complex with fibroblast growth factors and mediate signaling that controls cell differentiation proliferation and survival. Both VEGFR2 and FGFRs interact in ligand-receptor complexes to induce downstream signaling cascades for tissue vascular and development processes.
Pathways
VEGFR2 and FGFRs are integral to the MAPK and PI3K-Akt pathways. These pathways affect cellular responses such as growth and survival. VEGFR2's signaling interplays with proteins like PLCγ and Src to promote angiogenesis. FGFRs interact within the FGF signaling pathway connecting with proteins like SOS and Ras which regulate gene expression related to cell growth and differentiation.
VEGFR2 and FGFRs link to cancer and developmental syndromes. VEGFR2 is associated with pathological angiogenesis in various cancers and its overexpression can lead to tumor growth. Mutations in FGFRs cause disorders like skeletal dysplasia. Both VEGFR2 and FGFRs connect with other proteins such as PDGFR and EGFR influencing disease progression through altered signaling.